146 related articles for article (PubMed ID: 35739326)
1. Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study.
Holtan SG; Yu J; Paranagama D; Tang J; Choe HK; Naim A; Joachim Deeg H; Galvin J
Bone Marrow Transplant; 2022 Sep; 57(9):1399-1404. PubMed ID: 35739326
[TBL] [Abstract][Full Text] [Related]
2. Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review.
Holtan SG; Yu J; Choe HK; Paranagama D; Tang J; Naim A; Galvin J; Joachim Deeg H
Bone Marrow Transplant; 2022 Oct; 57(10):1581-1585. PubMed ID: 35908108
[TBL] [Abstract][Full Text] [Related]
3. Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation.
Yu J; Judy JT; Parasuraman S; Sinha M; Weisdorf D
Biol Blood Marrow Transplant; 2020 Mar; 26(3):600-605. PubMed ID: 31678539
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies for graft versus host disease with a focus on cell therapies.
Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG
Front Immunol; 2023; 14():1241068. PubMed ID: 37868964
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease.
Bell EJ; Yu J; Bhatt V; Bunner SH; Lal LS; Galvin J; Weisdorf D
Transplant Cell Ther; 2022 Oct; 28(10):707.e1-707.e7. PubMed ID: 35483620
[TBL] [Abstract][Full Text] [Related]
7. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
Park JH; Lee HJ; Kim SR; Song GW; Lee SK; Park SY; Kim KC; Hwang SH; Park JS
Korean J Intern Med; 2014 Sep; 29(5):630-6. PubMed ID: 25228839
[TBL] [Abstract][Full Text] [Related]
8. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
[TBL] [Abstract][Full Text] [Related]
9. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ
Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324
[TBL] [Abstract][Full Text] [Related]
10. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.
Weisdorf D; Haake R; Blazar B; Miller W; McGlave P; Ramsay N; Kersey J; Filipovich A
Blood; 1990 Feb; 75(4):1024-30. PubMed ID: 2302454
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
13. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
[TBL] [Abstract][Full Text] [Related]
14. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Murata M; Nakasone H; Kanda J; Nakane T; Furukawa T; Fukuda T; Mori T; Taniguchi S; Eto T; Ohashi K; Hino M; Inoue M; Ogawa H; Atsuta Y; Nagamura-Inoue T; Yabe H; Morishima Y; Sakamaki H; Suzuki R
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1183-9. PubMed ID: 23676716
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
[TBL] [Abstract][Full Text] [Related]
17. Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant.
Javed H; Chaudhry Q; Shahbaz N; Khan MA; Iftikhar R; Yousaf M
J Coll Physicians Surg Pak; 2022 Sep; 32(9):1225-1227. PubMed ID: 36089728
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
[TBL] [Abstract][Full Text] [Related]
19. Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
Tamaki M; Nakasone H; Misaki Y; Yoshimura K; Gomyo A; Hayakawa J; Kusuda M; Akahoshi Y; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
Ann Hematol; 2018 Oct; 97(10):1951-1960. PubMed ID: 29860563
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
Carnevale-Schianca F; Leisenring W; Martin PJ; Furlong T; Schoch G; Anasetti C; Appelbaum FR; Carpenter PA; Deeg HJ; Kiem HP; Storb R; McDonald GB; Nash RA
Biol Blood Marrow Transplant; 2009 Jun; 15(6):749-56. PubMed ID: 19450760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
